Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $13.1 million, a 98% increase from $6.6 million in Q3 2024, driven by the expansion of surgeon users and increased procedure volume [15][19] - Gross margins improved to 75.9% in Q3 2025 from 72.8% in Q3 2024, primarily due to lower contract manufacturing costs and reduced inventory reserve expenses [15][16] - Operating expenses increased to $19 million in Q3 2025 from $12.6 million in Q3 2024, with R&D expenses slightly rising to $4.4 million [16][17] - GAAP net loss was $8.5 million in Q3 2025 compared to a net loss of $7.8 million in Q3 2024 [17] Business Line Data and Key Metrics Changes - The surgeon user base grew by over 70% year over year, with minimal seasonal utilization headwinds in Q3 2025 [5][10] - The average revenue per procedure remained constant, indicating that revenue growth was driven by increased procedure volume rather than price changes [15] Market Data and Key Metrics Changes - The addressable market for Carlsmed's technology is estimated at $13 billion, with nearly 500,000 patients undergoing lumbar spine fusion procedures annually [6] - Recent clinical data showed an 83% reduction in reoperation rates for Aprivo procedures compared to traditional methods, enhancing the value proposition for hospitals and surgeons [11][34] Company Strategy and Development Direction - The company aims to transform spine surgery through a digital surgery platform that improves patient outcomes and reduces revision rates [6][12] - Key strategic focuses include commercial execution, surgeon education, and patient-centric innovation, with plans to launch Aprivo for cervical fusion procedures [12][13] - The company is leveraging clinical outcome data and economic value propositions to expand market access and surgeon engagement [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about ongoing durable growth, driven by surgeon enthusiasm and strategic investments in product and technology [21] - The company anticipates continued improvements in gross margins and operating leverage as it scales its business model [17][26] Other Important Information - Cash at September 30, 2025, was $115.5 million, bolstered by proceeds from the July IPO [18] - The company executed an expanded credit facility, increasing borrowing capacity to $50 million, providing financial flexibility for growth initiatives [18] Q&A Session Summary Question: Commentary on surgeon additions and utilization - Management noted strong surgeon enthusiasm in Q3, leading to higher-than-expected surgeon additions despite typical seasonal slowdowns [24] Question: Guidance on surgical ads and gross margin sustainability - Management indicated that gross margins of 76% are expected to be sustainable due to investments in supply chain efficiency [26][29] Question: Insights on the cervical launch and account characteristics - Early clinical evaluations for cervical procedures have been positive, with targeted accounts showing strong adoption [32] Question: Impact of new data on physician discussions - Recent long-term outcome data showing significant reductions in reoperation rates has positively influenced discussions with physicians [34] Question: Pipeline visibility and surgeon training time - Management expressed high confidence in pipeline visibility and ongoing investments in education to potentially shorten surgeon training time [44][46]